CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Cancer
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...
InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...
Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto
US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...
Zai Lab to Present Zejula OS Study Results at ESMO Congress
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...
Lepu and Keymed License CLDN18.2 ADC CMG901 to AstraZeneca
China-based firms Lepu Biopharma Co., Ltd (HKG: 2157) and Keymed Biosciences Inc. (HKG: 2162) have...
Abbisko’s ABSK121 Greenlit for Phase I Clinical Study by NMPA
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving the go-ahead from the...
Junshi Biosciences’ PD-1 Inhibitor Tuoyi Shows Promise in Phase III TNBC Study
Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced significant progress in the Phase...
Junshi Biosciences Seeks UK MHRA Approval for PD-1 Inhibitor Tuoyi
Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biotech firm, has announced the submission...
Wuhan Binhui’s Oncolytic Virus Therapy Awarded Breakthrough Designation by CDE
The Center for Drug Evaluation (CDE) website indicates that China-based Wuhan Binhui Biotechnology Co., Ltd’s...
CSPC’s NBL-020 Gets NMPA Approval for Clinical Study in Advanced Solid Tumors
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving the go-ahead from the National...
Topgen Biopharm Partners with Fudan University for Breast Cancer Gene Detection
Zhejiang-based tumor precision medicine specialist Topgen Biopharm Co., Ltd has entered into a strategic partnership...
Shanghai-Based REMD Raises Series A+ Funding for Electroporation Device Expansion
Shanghai-based REMD, a leading manufacturer of irreversible electroporation devices, has reportedly raised over RMB 100...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...
Harbour BioMed Licenses HBM7008 to Cullinan Oncology for US Development
Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...
Gracell Biotechnologies Gains IND Approval for GC012F in China
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...